MARATTO

article · BMC Women s Health

Uncommon metastatic journey: unusual breast metastases of medullary thyroid carcinoma: a case report

20252 citationsOpen accessUniversity of Tunis El Manar

Abstract

Medullary thyroid carcinoma is a neuroendocrine tumor derived from thyroid C-cells. It is a rare aggressive tumor, known to metastasize to lymph nodes, liver, bones, and lungs. We report a case of a young patient with a family history of breast cancer, who developed breast metastases six months post-treatment for medullary thyroid carcinoma. The breast lesion was initially considered benign in ultrasound. Unlike the high prevalence of primary mammary malignancies, metastases to the breast are uncommon, and account for only 0.2-2.7% of all malignancies affecting this organ. This case emphasizes the need for thorough and continuous monitoring of patients with Medullary thyroid carcinoma, even in unusual locations, to ensure early detection and appropriate management. New lesions on imaging should be interpreted with caution to avoid underdiagnosing metastasis. Immunohistochemical analysis confirmed the metastatic origin, underscoring the challenges in distinguishing between primary and secondary breast tumors. This case contributes to the limited literature on MTC breast metastases and advocates for heightened clinical awareness regarding atypical metastatic sites in thyroid cancer patients.

Research topics

  • Thyroid Cancer Diagnosis and Treatment
  • Cancer Diagnosis and Treatment
  • Breast Lesions and Carcinomas

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s12905-025-03564-y

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.